Carsten Schwarz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Carsten Schwarz has a total of 925 co-authors. Here are the top co-authors by number of shared publications:
Doris Staab
Department of Pediatric Pneumology, Immunology and Intensive Care Medicine, CF Center / Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany
7 shared publicationsClaudia Brandt
Christiane Herzog Zentrum Berlin/Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany
6 shared publicationsAnja Thronicke
Department of Pediatric Pneumology and Immunology, Cystic Fibrosis Center Berlin/Charité –Universitätsmedizin Berlin, Berlin, Germany
4 shared publications- Astrid Lewin
Unit 16 Mycotic and Parasitic Agents and Mycobacteria, Robert Koch Institute, Berlin, Germany
4 shared publications - Graham F. Peaslee
University of Notre Dame
4 shared publications - ManYee Betty Tsang
Facility for Rare Isotope Beams Michigan State University 48824 East Lansing Michigan USA
4 shared publications
Latest Publications
- Open Access
- 24 May 2024
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 23 (3) , 375-387
Standards for the care of people with cystic fibrosis (CF); Planning for a longer life
- 24 May 2024
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 23 (3) , 375-387
Open AccessStandards for the care of people with cystic fibrosis (CF); Planning for a longer life
- 19 March 2024
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 23 (4) , 590-602
ECFS standards of care on CFTR-related disorders: Identification and care of the disorders
- 19 March 2024
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 23 (4) , 590-602
ECFS standards of care on CFTR-related disorders: Identification and care of the disorders
- 7 October 2023
- Published by Taylor & Francis
- p. 281-291
Fungal Diseases in CF
In cystic fibrosis (CF), the main focus in the field of bronchopulmonary infection is on bacteria, as they have the highest influence on the lung function as well as on the exacerbation rate. In recent decades, more attention was paid to fungal pulmonary diseases as they might have a significant impact on the clinical course of people with CF. In the past decades, studies on diagnostic tools such as biomarkers for allergic bronchopulmonary aspergillosis and diagnostic and therapeutic guidelines have been performed. Studies showed a negative impact on lung function in people with CF and detected different entities or categories, namely: colonisation, sensitisation, bronchitis, pneumonia, allergic bronchopulmonary aspergillosis, pneumonia, and aspergilloma. New definitions and treatment recommendations have been established for bronchitis, pneumonia, and allergic bronchopulmonary aspergillosis. Both multi- and single-centre studies, as well as patient registry data analyses reveal a significant impact of fungal pulmonary diseases on clinical courses of people with CF. Definitions and treatment recommendations have been implemented to improve the outcome of people with CF.
- 7 October 2023
- Published by Taylor & Francis
- p. 281-291
Fungal Diseases in CF
In cystic fibrosis (CF), the main focus in the field of bronchopulmonary infection is on bacteria, as they have the highest influence on the lung function as well as on the exacerbation rate. In recent decades, more attention was paid to fungal pulmonary diseases as they might have a significant impact on the clinical course of people with CF. In the past decades, studies on diagnostic tools such as biomarkers for allergic bronchopulmonary aspergillosis and diagnostic and therapeutic guidelines have been performed. Studies showed a negative impact on lung function in people with CF and detected different entities or categories, namely: colonisation, sensitisation, bronchitis, pneumonia, allergic bronchopulmonary aspergillosis, pneumonia, and aspergilloma. New definitions and treatment recommendations have been established for bronchitis, pneumonia, and allergic bronchopulmonary aspergillosis. Both multi- and single-centre studies, as well as patient registry data analyses reveal a significant impact of fungal pulmonary diseases on clinical courses of people with CF. Definitions and treatment recommendations have been implemented to improve the outcome of people with CF.
- 1 January 2022
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 21 (1) , 136-142
Clinician variability in the diagnosis and treatment of aspergillus fumigatus-related conditions in cystic fibrosis: An international survey
- 1 January 2022
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 21 (1) , 136-142
Clinician variability in the diagnosis and treatment of aspergillus fumigatus-related conditions in cystic fibrosis: An international survey
- 1 November 2021
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 20 (6) , 1035-1039
Clinical impact of levofloxacin inhalation solution in cystic fibrosis patients in a real-world setting
- 1 November 2021
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 20 (6) , 1035-1039
Clinical impact of levofloxacin inhalation solution in cystic fibrosis patients in a real-world setting
- Open Access
- 1 November 2021
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 20 (6) , e87-e92
Risk factors for cystic fibrosis arthropathy: Data from the German cystic fibrosis registry
- 1 November 2021
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 20 (6) , e87-e92
Open AccessRisk factors for cystic fibrosis arthropathy: Data from the German cystic fibrosis registry
- Open Access
- 21 September 2021
- Published by Taylor & Francis in Virulence
- Vol. 12 (1) , 2415-2429
Genetic diversification of persistent Mycobacterium abscessus within cystic fibrosis patients
Mycobacterium (M.) abscessus infections in Cystic Fibrosis (CF) patients cause a deterioration of lung function. Treatment of these multidrug-resistant pathogens is associated with severe side-effects, while frequently unsuccessful. Insight on M. abscessus genomic evolvement during chronic lung infection would be beneficial for improving treatment strategies. A longitudinal study enrolling 42 CF patients was performed at a CF center in Berlin, Germany, to elaborate phylogeny and genomic diversification of in-patient M. abscessus. Eleven of the 42 CF patients were infected with M. abscessus. Five of these 11 patients were infected with global human-transmissible M. abscessus cluster strains. Phylogenetic analysis of 88 genomes from isolates of the 11 patients excluded occurrence of M. abscessus transmission among members of the study group. Genome sequencing and variant analysis of 30 isolates from 11 serial respiratory samples collected over 4.5 years from a chronically infected patient demonstrated accumulation of gene mutations. In total, 53 genes exhibiting non-synonymous variations were identified. Enrichment analysis emphasized genes involved in synthesis of glycopeptidolipids, genes from the embABC (arabinosyltransferase) operon, betA (glucose-methanol-choline oxidoreductase) and choD (cholesterol oxidase). Genetic diversity evolved in a variety of virulence- and resistance-associated genes. The strategy of M. abscessus populations in chronic lung infection is not clonal expansion of dominant variants, but to sustain simultaneously a wide range of genetic variants facilitating adaptation of the population to changing living conditions in the lung. Genomic diversification during chronic infection requires increased attention when new control strategies against M. abscessus infections are explored.
- 21 September 2021
- Published by Taylor & Francis in Virulence
- Vol. 12 (1) , 2415-2429
Open AccessGenetic diversification of persistent Mycobacterium abscessus within cystic fibrosis patients
Mycobacterium (M.) abscessus infections in Cystic Fibrosis (CF) patients cause a deterioration of lung function. Treatment of these multidrug-resistant pathogens is associated with severe side-effects, while frequently unsuccessful. Insight on M. abscessus genomic evolvement during chronic lung infection would be beneficial for improving treatment strategies. A longitudinal study enrolling 42 CF patients was performed at a CF center in Berlin, Germany, to elaborate phylogeny and genomic diversification of in-patient M. abscessus. Eleven of the 42 CF patients were infected with M. abscessus. Five of these 11 patients were infected with global human-transmissible M. abscessus cluster strains. Phylogenetic analysis of 88 genomes from isolates of the 11 patients excluded occurrence of M. abscessus transmission among members of the study group. Genome sequencing and variant analysis of 30 isolates from 11 serial respiratory samples collected over 4.5 years from a chronically infected patient demonstrated accumulation of gene mutations. In total, 53 genes exhibiting non-synonymous variations were identified. Enrichment analysis emphasized genes involved in synthesis of glycopeptidolipids, genes from the embABC (arabinosyltransferase) operon, betA (glucose-methanol-choline oxidoreductase) and choD (cholesterol oxidase). Genetic diversity evolved in a variety of virulence- and resistance-associated genes. The strategy of M. abscessus populations in chronic lung infection is not clonal expansion of dominant variants, but to sustain simultaneously a wide range of genetic variants facilitating adaptation of the population to changing living conditions in the lung. Genomic diversification during chronic infection requires increased attention when new control strategies against M. abscessus infections are explored.
- Open Access
- 4 November 2020
- Published by Springer Nature in Scientific Reports
- Vol. 10 (1) , 1-9
Risk factors for respiratory Aspergillus fumigatus in German Cystic Fibrosis patients and impact on lung function
Airway inflammation and chronic lung infections in cystic fibrosis (CF) patients are mostly caused by bacteria, e.g. Pseudomonas aeruginosa (PA). The role of fungi in the CF lung is still not well elucidated, but evidence for a harmful and complex role is getting stronger. The most common filamentous fungus in CF is Aspergillus fumigatus (AF). Age and continuous antibiotic treatment have been discussed as risk factors for AF colonisation but did not differentiate between transient and persistent AF colonisation. Also, the impact of co-colonisation of PA and AF on lung function is still under investigation. Data from patients with CF registered in the German Cystic Fibrosis Registry database in 2016 and 2017 were retrospectively analysed, involving descriptive and multivariate analysis to assess risk factors for transient or persistent AF colonisation. Age represented an independent risk factor for persistent AF colonisation. Prevalence was low in children less than ten years, highest in the middle age and getting lower in higher age (≥ 50 years). Continuous antibiotic lung treatment was significantly associated with AF prevalence in all age groups. CF patients with chronic PA infection had a lower lung function (FEV1%predicted), which was not influenced by an additional AF colonisation. AF colonisation without chronic PA infection, however, was significantly associated with a lower function, too. Older age up to 49 years and continuous antibiotic use were found to be the main risk factors for AF permanent colonisation. AF might be associated with decrease of lung function if not disguised by chronic PA infection.
- 4 November 2020
- Published by Springer Nature in Scientific Reports
- Vol. 10 (1) , 1-9
Open AccessRisk factors for respiratory Aspergillus fumigatus in German Cystic Fibrosis patients and impact on lung function
Airway inflammation and chronic lung infections in cystic fibrosis (CF) patients are mostly caused by bacteria, e.g. Pseudomonas aeruginosa (PA). The role of fungi in the CF lung is still not well elucidated, but evidence for a harmful and complex role is getting stronger. The most common filamentous fungus in CF is Aspergillus fumigatus (AF). Age and continuous antibiotic treatment have been discussed as risk factors for AF colonisation but did not differentiate between transient and persistent AF colonisation. Also, the impact of co-colonisation of PA and AF on lung function is still under investigation. Data from patients with CF registered in the German Cystic Fibrosis Registry database in 2016 and 2017 were retrospectively analysed, involving descriptive and multivariate analysis to assess risk factors for transient or persistent AF colonisation. Age represented an independent risk factor for persistent AF colonisation. Prevalence was low in children less than ten years, highest in the middle age and getting lower in higher age (≥ 50 years). Continuous antibiotic lung treatment was significantly associated with AF prevalence in all age groups. CF patients with chronic PA infection had a lower lung function (FEV1%predicted), which was not influenced by an additional AF colonisation. AF colonisation without chronic PA infection, however, was significantly associated with a lower function, too. Older age up to 49 years and continuous antibiotic use were found to be the main risk factors for AF permanent colonisation. AF might be associated with decrease of lung function if not disguised by chronic PA infection.
- 6 October 2020
- Published by Georg Thieme Verlag KG in DMW - Deutsche Medizinische Wochenschrift
- Vol. 145 (20) , 1486-1489
Therapie der Mukoviszidose – neue Medikamente geben Hoffnung
Was ist neu?: Therapieansatz Bis vor kurzem bestand die medikamentöse Therapie der Mukoviszidose nur aus einer rein symptomatischen Therapie, aber der Defekt des Chloridkanals konnte nicht beeinflusst werden. Mit der CFTR-Modulatortherapie besteht nun erstmals eine ursächliche und effiziente Therapie, die eine Verbesserung der Lungenfunktionswerte erzielt wie keine der bisherigen Therapien.
- 6 October 2020
- Published by Georg Thieme Verlag KG in DMW - Deutsche Medizinische Wochenschrift
- Vol. 145 (20) , 1486-1489
Therapie der Mukoviszidose – neue Medikamente geben Hoffnung
Was ist neu?: Therapieansatz Bis vor kurzem bestand die medikamentöse Therapie der Mukoviszidose nur aus einer rein symptomatischen Therapie, aber der Defekt des Chloridkanals konnte nicht beeinflusst werden. Mit der CFTR-Modulatortherapie besteht nun erstmals eine ursächliche und effiziente Therapie, die eine Verbesserung der Lungenfunktionswerte erzielt wie keine der bisherigen Therapien.